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Abstract  
Exocytosis of the hormone, glucagon-like peptide-1 (GLP-1), by the intestinal L-cell is 
essential for the incretin effect after nutrient ingestion, and is critical for the actions of 
dipeptidylpeptidase IV inhibitors that enhance GLP-1 levels in patients with type 2 diabetes. 2-
Photon microscopy revealed that exocytosis of GLP-1 is biphasic, with a 1
st
 peak at 1-6min and a 
2
nd
 peak at 7-12min after stimulation with forskolin. Approximately 75% of the exocytotic 
events were represented by compound granule fusion, and the remainder were accounted for by 
full fusion of single granules, under basal and stimulated conditions. The core SNARE protein, 
syntaxin-1a (syn1a), was expressed by murine ileal L-cells. At the single L-cell level, 1
st
 phase 
forskolin-induced exocytosis was reduced to basal (p<0.05) and 2
nd
 phase exocytosis was 
abolished (p<0.05) by syn1a knockout. L-cells from intestinal-epithelial syn1a-deficient mice 
demonstrated a 63% reduction in forskolin-induced GLP-1 release in vitro (p<0.001), and a 23% 
reduction in oral glucose-stimulated GLP-1 secretion (p<0.05) in association with impairments in 
glucose-stimulated insulin release (by 60%, p<0.01) and glucose tolerance (by 20%, p<0.01). 
Our findings therefore identify an exquisite mechanism of metered secretory output that 
precisely regulates release of the incretin hormone, GLP-1 and, hence, insulin secretion 
following a meal. 
 
Keywords: 2-photon microscopy, exocytosis, GIP, GLP-1, GLP-2, intestine, knockout, OGTT, 
oxyntomodulin, primary cells, proglucagon-Venus, secretion, villin-cre 
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Introduction 
The incretin hormone, glucagon-like peptide-1 (GLP-1), plays an essential role in the 
maintenance of normoglycemia, through enhancement of glucose-dependent insulin secretion 
and suppression of glucagon release, gastric emptying and appetite (1, 2). As a consequence of 
these beneficial actions, GLP-1 receptor agonists are now widely-utilized to treat patients with 
type 2 diabetes (T2D) and obesity. In contrast to the actions of GLP-1-derivative drugs, 
therapeutic dipeptidylpeptidase IV (DPP IV) inhibitors prevent the degradation of endogenously-
secreted GLP-1, as well as of the other incretin hormone, glucose-dependent insulinotropic 
peptide (GIP) (3, 4). The possibility of utilizing GLP-1 secretagogues, alone or in combination 
with DPP IV inhibition, has therefore engendered considerable interest as a new approach to 
incretin therapy (5-7).   
Hormone secretion by the intestinal L-cell which includes, not only GLP-1 but also the 
related peptides, GLP-2 and oxyntomodulin, demonstrates two peaks of release following 
nutrient ingestion (8, 9). Rodent studies have demonstrated that part of the early peak of GLP-1 
secretion is mediated indirectly, through vagal pathways originating in the duodenum that 
activate muscarinic receptors on the distal L-cell (10-12). In contrast, the later peak of GLP-1 
release is initiated by direct contact of luminal nutrients with the L-cell, resulting in transporter- 
and ion channel-mediated depolarization, as well as activation of multiple G protein-coupled 
receptors (13-16). Many of these receptors are expressed not only by the intestinal L-cell, but 
also by the pancreatic β-cell (17), consistent with the coordinated release of GLP-1 and insulin in 
vivo.  However, in contrast to the β-cell, for which the signaling pathways regulating insulin 
secretion are well-established (18), much less is known about the intestinal L-cell.  
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Glucose-mediated depolarization of the β-cell opens voltage-gated calcium channels, 
thereby activating the calcium-sensor, synaptotagmin-7 (19). This relieves the clamping action of 
synaptogamin-7 on the SNARE fusion machinery, which consists of the vesicle SNARE protein, 
VAMP, and the plasma membrane SNAREs, syntaxin (syn) and SNAP23/25 (20), thus 
permitting insulin exocytosis. Although the β-cell expresses several SNARE isoforms, VAMP2 
and syn1a are most important for 1
st
 phase glucose-stimulated insulin secretion (GSIS), with 
VAMP8 and syn3/4 contributing to both 1
st
 and 2
nd
 phase release (21-23). The SNARE proteins 
also mediate several different types of exocytotic events in the β-cell. Thus, predocked secretory 
granules (SGs) contribute predominantly to 1
st
 phase secretion, whereas newcomer granules 
recruited from an intracellular reserve pool account for some of 1
st
 phase and practically all of 
2
nd
 phase insulin exocytosis (24). Furthermore, these SGs also undergo temporally and 
physically distinct types of fusion with the plasma membrane, termed full, sequential, compound 
and kiss-and-run (24-29).  
While one study has demonstrated a role for synaptotagmin-7 in GLP-1 secretion (30), 
little is known about the role of the core SNARE proteins in the L-cell. We have reported that the 
murine GLUTag L-cell line expresses multiple isoforms of VAMP and syn, as well as SNAP25 
(31). VAMP2 was demonstrated to play an important role in GLP-1 secretion by these cells, and 
was also found to be expressed in primary mouse intestinal L-cells. Furthermore, VAMP2 co-
immunoprecipitates with syn1a and SNAP25 in the GLUTag cells, suggesting these SNARE 
proteins form a functional exocytotic complex in the L-cell. Given the current interest in 
therapeutic approaches to enhance release of GLP-1 into the circulation (5-7), we have now 
utilized novel knockout mouse models in vivo and ex vivo, in combination with single-cell 
visualization of exocytosis, to interrogate GLP-1 release by the primary intestinal L-cell. We 
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show that GLP-1 release is biphasic, as mediated primarily by multi-granular (i.e. compound) 
fusion under both basal and stimulated conditions, and that the SNARE protein, syn1a, plays an 
essential role in the exocytosis of GLP-1. These findings identify novel regulatory mechanisms 
that underlie secretion of the incretin hormone, GLP-1, and have implications to the development 
of GLP-1 secretagogues for therapeutic use in the treatment of T2D and obesity.  
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Methods 
Animals Male C57Bl/6 mice (7-12 wk) were from Charles River. Female syn1a
fl/fl
 (32) were 
crossed with male villin-creER
T2+/0
 (B6-Tg(Vil-cre/ERT2)23Syr) (33, 34) mice and the resultant 
tamoxifen-inducible intestinal-epithelial syn1a
fl/fl
;villin-creER
T2+/0
 (IE-syn1a KO) animals were 
crossed with proglucagon (Gcg)-Venus mice (35) to generate Venus-IE-syn1a KO animals (see 
Table S1 for primers).  Age- (7-12 wk) and sex-matched male and female littermates were 
studied, and controls included: vehicle- and tamoxifen (1 mg/100 µl sunflower oil, ip for 5 d)-
treated syn1a
fl/fl
, villin-creER
T2+/0
, syn1a
fl/-
;villin-creER
T2+/0
 and syn1a
fl/-
;villin-creER
T2+/0
;Gcg-
Venus mice, as well as vehicle-treated syn1a
fl/fl
;villin-creER
T2+/0
 and syn1a
fl/fl
;villin-
creER
T2+/0
;Gcg-Venus animals, as appropriate for the KO model being studied. Two-three days 
after induction, mice were fasted overnight followed by an oral or intraperitoneal glucose 
tolerance test (OGTT: 5g/kg glucose; as previously shown to optimize GLP-1 release in mice 
(36); and IPGTT: 3 g/kg glucose, as determined in pilot studies to match the glycemic response 
observed in the OGTT, data not shown) and tail-vein blood collection. Glycemia was determined 
using a glucose meter (OneTouch, LifeScan), and plasma total GLP-1 (Mesoscale Discovery), 
total GIP (Millipore) and  insulin (Crystal Chem) by kit-assay, as reported (37). Due to their high 
concentration of L-cells (38), ileal segments were collected for primary culture and analyses. All 
animal protocols were approved by the Animal Care Committee of the University of Toronto.  
Adult mouse ileal crypt (AMIC) cultures Isolated crypts from 10-cm mouse ileum were plated 
overnight, as reported (35). Two-hr secretion assays were followed by ELISA (Millipore) for 
active GLP-1 levels in media and cells, as reported (12, 35). Secretion was calculated as the 
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percent of total culture content that was detected in the media. Experiments were conducted in 
quadruplicate wells to make n=1 per mouse. 
2-Photon microscopy was performed on AMIC cultures perfused at 2 ml/min and 30 
o
C. 
Sulforhodamine-B (0.8 mM) (25) was added 2-3 min prior to visualization using a Nikon A1R 
multi-photon microscope, for up to 3 min (basal) followed by 12 min with 50 µM forskolin. L-
cells were identified by Venus (YFP) fluorescence, and the cell membrane was defined by the 
extracellular localization of sulforhodamine-B. Data were analysed with NIS-Elements software 
(Nikon). Focal events that occurred over ≤10 sec were classified as full fusion, whereas events of 
longer duration were considered to be compound fusion.  
Morphometric and immunometric analyses Crypt-villus height was measured in hematoxylin & 
eosin-stained ileal sections in a minimum of 20 well-oriented axes per mouse. Ileal sections and 
AMIC cultures were stained for syn1a and GLP-1 (see Table S2 for antibodies), followed by 
visualization using a Zeiss deconvolution microscope and analysis of fluorescence intensity 
using ImageJ# (39). Negative controls omitted the primary antisera. 
Molecular analyses Ileal Venus
+
 and Venus
-
 cells were collected from female Gcg-Venus mice 
(n=3) by fluorescence-activated cell sorting. Barcode-ligation and end repair were achieved 
using the Ovation Rapid DR Multiplex System 1–96 (NuGEN). Combined barcoded libraries 
underwent SE50 sequencing using an Illumina HiSeq 2500 system (Genomics Core Facility, 
Cancer Research UK Cambridge Institute). Sequence reads were demultiplexed using the Casava 
pipeline (Illumina) and aligned to the mouse genome (GRCm38) using Tophat-v2.1.0 
(http://ccb.jhu.edu/software/tophat/index.shtml). Differential gene expression was determined 
using Cufflinks-v2.2.1 (http://cole-trapnell-lab.github.io/cufflinks/), as reported (35).  
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Total RNA from ileal mucosal scrapes and AMIC cultures was reverse-transcribed and 
analyzed by PCR with primer/probe sets from Applied Biosystems (Table S3). Histone 3A was 
used as the internal control for analysis by the ∆∆Ct method.  
Adenovirus studies: Syn1a
fl/fl
 mice were anesthetized, laparotomized and 0.75 ml of 0.9-1.8x10
8
 
infection units/ml Adenovirus-RFP-improved cre-recombinase (Adv-iCre) or Adv-RFP (control; 
Vector Biolabs) was injected into the distal ileal lumen. Animals recovered for 2d and were then 
re-laparotomized and 0.75 ml oleoylethanolamide (OEA; 15 µM) was injected into the ileum 
followed by sampling for analysis of glycemia, plasma hormone levels and ileal gene expression, 
as above.  
AMIC cultures were infected with 2.4x10
7
 IFU/ml Adv-iCre or Adv-RFP for 48 hr, 
followed by a 2 hr GLP-1 secretion assay and analysis by ELISA and qRT-PCR, as above. 
Statistical Analyses Data are shown as mean ± SEM. Statistical differences were determined by 
Student’s t test or 1- or 2-way ANOVA followed by Student’s t test or Tukey multiple 
comparison test, as appropriate.  
  
Page 8 of 79
For Peer Review Only
Diabetes
9 
 
Results 
Immunostaining of the ileum from normal mice revealed expression of syn1a in GLP-1-
expressing cells, as well as in other cells in the crypt and scattered through the villous epithelium 
(Figure 1A).  We also examined co-localization of GLP-1 and syn1a in AMIC cultures, a 
valuable ex vivo model for the study of GLP-1 secretion by primary L-cells (35) (Figure 1B). 
Importantly, of the 1.1 ± 0.1% of all AMIC cells that were GLP-1-positive (n=1670-5095 cells 
each in 6 independent cultures), 100% were found to co-express syn1a. Confirming specificity of 
the syn1a staining, AMIC cultures generated from intestinal-epithelial syn1a knockout (IE-syn1a 
KO) mice demonstrated a significant loss of syn1a staining in the L-cells (p<0.001) as well as 
more globally in other, unidentified crypt cells (Figure 1C-D).  
GLP-1 secretion by AMIC cultures from normal mice was increased to 2.3-fold of 
control (p<0.01) in response to treatment with forskolin plus 3-isobutyl-1-methylxanthine 
(IBMX), without any change in GLP-1 synthesis (Figures 1E-F). Similarly, treatment with the 
physiological secretagogues, GIP (Figure 1G) and the GPR119 agonist, oleoylethanolamide 
(OEA; Figure 1H) enhanced GLP-1 release, to 1.7- and 3.5-fold of control (p<0.05-0.001), 
respectively. These findings suggest a role for syn1a in L-cell secretion and support use of both 
the IE-syn1a KO mouse model and AMIC cultures in further studies to assess this hypothesis.  
Compared to control animals, IE-syn1a KO mice demonstrated increases in body (Figure 
2A) and intestinal (Figure 2B) weight 7-12 days following the completion of daily tamoxifen 
injections (p<0.05-0.001). However, upon normalization of intestinal weight to body weight, the 
observed increase in intestinal weight was maintained only in male animals lacking syn1a 
(Figures 2C and S1), suggestive of sexual dimorphism. Morphologic characterization of the 
Page 9 of 79
For Peer Review Only
Diabetes
10 
 
intestinal epithelium further revealed that IE-syn1a KO animals had a small but significant 
increase in crypt depth (p<0.01; Figure 2D). Furthermore, the 39% reduction of syn1a (i.e. 
Stx1a) mRNA observed in intestinal mucosal scrapes from KO animals (p<0.05; Figure 2E) was 
associated with increases in the expression of Stx1b and -2 (p<0.05-0.01; Figure 2F). While the 
function of syn1b in the intestinal epithelium is not known, it appears to play a role in mast cell 
degranulation (40). In contrast, Stx2 (aka epimorphin) expression in mesenchymal cells abutting 
the epithelium has been shown to regulate the morphology of the crypt-to-villus axis (41), 
suggesting a role in the observed increase in crypt depth. Examination of two other syn isoforms 
that are also localized to the plasma membrane, Stx3 and -4  (42), did not reveal any other 
adaptive changes (Figure 2F).  
To determine whether intestinal-epithelial syn1a has any relationship to glucose 
tolerance, we performed an oral glucose tolerance test (OGTT) in control and IE-syn1a KO mice 
two-days following completion of tamoxifen or vehicle injection. IE-syn1a KO animals 
displayed a significant impairment in glucose tolerance, with blood glucose levels reaching 1.3- 
and 1.4-fold of controls at t=45 (p<0.05) and 60 min (p<0.001), respectively (Figure 3A). 
Accordingly, the 2-hr glycemic area-under-the-curve in IE-syn1aKO mice was also significantly 
increased, to 1.2-fold of controls (p<0.01; Figure 3B).  Consistent with this finding, IE-syn1a KO 
mice showed a reduction in plasma insulin levels as compared with controls, which reached 
statistical significance at t=60 min (Figure 3C). Furthermore, basal GLP-1 levels were 17% 
lower in IE-syn1a KO mice than in controls (p<0.05), with an even further reduction at t=10 min 
post-oral glucose administration (by 23%, p<0.05 vs. basal; p<0.01 vs. the difference at t=0 min; 
Figure 3D). Analyzing these data for sexual dimorphism showed that male but not female IE-
syn1a KO animals accounted for the glucose intolerance and reduced plasma insulin levels 
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observed during the OGTT (Figure S2). However, plasma GLP-1 levels were consistently 
reduced in both male and female IE-syn1a KO animals (Figure S3A). Gene expression analysis 
of the GLP-1 prohormone, proglucagon (Gcg), in the intestinal mucosa showed no difference 
between KO and control animals (Figure 2F), indicating that the reduced GLP-1 levels in IE-
syn1a KO mice are not due to a deficiency in GLP-1 production. Similar to the reduction in 
GLP-1 levels, both male and female IE-syn1a KO animals also displayed significantly lower 
plasma GIP concentrations, by 31 - 53% at t=0, 10 and 60 min (p<0.05-0.01; Figures 3E and 
S3B). Furthermore, a requirement for the incretin hormones in the impaired glucose tolerance of 
KO animals was confirmed by the demonstration that mice with loss of intestinal-epithelial 
syn1a had normal glucose tolerance in response to an IPGTT (Figure 3F). Together, these data 
suggest that the compromised glucose homeostasis in IE-syn1a KO animals occurs, at least in 
part, as a result of reductions in both GLP-1 and GIP secretion.  
To confirm that loss of syn1a impairs L-cell secretory function, AMIC cultures were 
generated from crypts isolated from IE-syn1a KO and control animals. Interestingly, IE-syn1a 
KO AMIC cultures were found to have a 78% reduction in Stx1a expression (p<0.01; Figure 
4A). This more profound knock-down in the crypt cultures compared to the mucosal scrapes is 
likely a consequence of epithelial cell enrichment in the cultures, whereas both villus epithelial 
and non-villin-expressing syn1a-positive cells contribute to the syn1a signal in the scrapes. We 
also examined the Stx1b, -2, -3 and -4 isoforms in the AMIC cultures and found no differences in 
expression (Figure 4B), further suggesting that adaptive changes that were observed in the 
mucosa were independent of the intestinal-epithelial cells.   
Secretion assays with AMIC cultures generated from IE-syn1a KO mice demonstrated no 
difference in basal GLP-1 secretion as compared to control animals (Figure 4C). However, IE-
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syn1a KO mice displayed a 2.6-fold reduction in forskolin-stimulated GLP-1 secretion, to 37% 
of the response found in controls (p<0.001; Figure 4C). Total GLP-1 content of the cultured cells 
did not differ between the genotypes or treatment groups (Figure 4D). Gcg gene expression also 
did not differ as a result of loss of syn1a (Figure 4B), further suggesting that the reduced GLP-1 
secretion is a result of disrupted L-cell secretory function.  
To more directly examine the role of syn1a in GLP-1 secretion by the primary L-cell, we 
initially conducted in vivo and in vitro studies utilizing adenovirus-mediated knockdown of 
syn1a. However, application of the control adenovirus alone blunted the ability of the intestinal 
L-cells to respond to known secretagogues, making this an inappropriate model for further study 
(Figure S4). We therefore crossed the IE-syn1a KO animals with mice expressing Venus under 
the control of the Gcg promoter (35) to permit identification of the L-cell for exocytotic analysis. 
While Venus-IE-syn1a KO mice did not show any changes in body weight, they were found to 
have increased intestinal weight which, following normalization to body weight, was maintained 
only in male animals lacking syn1a (Figures 5A-C and S5). This pattern was very similar to that 
observed in the IE-syn1a KO mice that did not express Gcg-Venus (Figure S1). Furthermore, 
although Stx1a expression was reduced by 58% (p<0.05) in the intestinal mucosa (Figure 5D), 
there were no significant changes in expression of Stx1b and -2 (Figure 5E). However, an OGTT 
revealed that Venus-IE-syn1a KO animals, like the IE-syn1a KO mice, had impaired glucose 
tolerance, with significantly elevated glycemia at t=60 min after oral glucose administration in 
comparison to controls (1.3-fold of control values, p<0.05; Figure 5F). Like the IE-syn1a KO 
mice, these animals also demonstrated sexual dimorphism, with significant changes found only 
in the male mice (Figure S6). Collectively, these findings suggested an impairment in GLP-1 
secretion in the Venus-IE-syn1a KO animals, despite the finding of a 1.8-fold increase in 
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intestinal mucosal Gcg gene expression (p<0.05; Figure 5D).    
As the heterogonous cell population of both the ileal mucosa and isolated ileal crypt 
cultures limits our understanding of L-cell specific gene expression, we compiled a syntaxin 
isoform expression profile from Venus-positive L-cells by RNAseq (Figure 5G). Of the four syn 
isoforms known to be localized on the plasma membrane, only Stx1a appeared to be enriched (by 
3.6-fold) in the Venus-positive L-cells as compared to Venus-negative intestinal-epithelial cells. 
Collectively, these data further suggest a role for syn1a in GLP-1 exocytosis, and validate the use 
of the Venus-IE-syn1a KO mice as a model for our studies.   
As exocytosis by the primary intestinal L-cell has not previously been described, we 
utilized 2-photon microscopy to visualize SG fusion events in Venus-positive L-cells from both 
control and Venus-IE-syn1a KO mice, under basal and 50 µM forskolin-stimulated conditions 
(Figures 6A and S7). In the absence of forskolin, all of the Venus-positive and some of the 
Venus-negative cells demonstrated periodic exocytotic events; an increase in exocytosis in both 
cell types was noted upon the addition of forskolin. However, interestingly, some cells 
demonstrated a profound level of activity as compared to the surrounding cells, with a large 
granule size that is consistent with the known characteristics of mast cells (Supplemental Video 
1) (43). As has been reported for the β-cell (24-29), distinct types of exocytotic events were 
observed in Venus-positive L-cells from control animals. Thus, throughout the duration of our 
recordings, we identified both single (full; Supplemental Video 2) and multi-granular 
(compound; Supplemental Video 3) SG fusions that differed in the size of the signal and the 
duration of the event (Figure 6A).     
The pattern of fusion events observed in L-cells from Venus-control mice was strongly 
indicative of biphasic exocytosis. Hence, after the basal period, the addition of forskolin 
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stimulated a 1
st
-phase of exocytosis at 1-6 min, followed by a 2
nd
 phase at 7-12 min (Figure 6B, 
D and E). In comparing single L-cells from Venus-IE-syn1a KO and Venus-control mice, there 
was no obvious change in the number of SG fusion events during the basal period (Figure 6B-E). 
However, recordings from Venus-IE-syn1a KO L-cells demonstrated that syn1a depletion 
dramatically reduced the number of SG fusion events under stimulating conditions, such that 1
st
 
phase exocytosis was reduced to basal levels (p<0.05) and 2
nd
 phase was abolished (p<0.05). 
Finally, determination of the contributions of full and compound fusion events to each phase of 
secretion revealed that L-cell exocytosis is largely mediated by compound fusion (approximately 
75% of total events), under both basal and stimulated conditions (Figure 6D). Importantly, in the 
absence of syn1a, the reduced number of SG fusion events in both 1
st
 and 2
nd
 phase secretion was 
attributed to the loss of both full and compound fusion. This result demonstrates the preservation 
of SG fusion competence under basal conditions but a requirement for syn1a in stimulated SG 
fusion in the primary L-cell. When taken together, these data illuminate the spatio-temporal 
activity of the SG exocytosis that underlies GLP-1 secretion.  
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Discussion  
The actions of the incretin hormones, GLP-1 and GIP, account for ~50% of the insulin 
response to nutrient ingestion (44, 45).  However, despite the importance of GLP-1 to glucose 
homeostasis, major gaps remain in our understanding of the molecular machinery that regulates 
GLP-1 release. Although studies on the primary L-cell have been limited in the past due, in large 
part, to the diffuse dispersion of these cells throughout the intestinal epithelium (38), recent 
advances now permit direct visualization of exocytosis by reporter-labelled L-cells ex vivo 
following primary culture (35). Using these approaches, the findings of the present study 
demonstrate the dynamics of SG fusion to the plasma membrane of the primary intestinal L-cell, 
and the essential role of the core SNARE protein, syn1a, in secretagogue-induced exocytosis of 
GLP-1.  
2-Photon microscopy demonstrated that exocytosis by the primary L-cell is mediated 
through different types of exocytotic events, of which the majority are compound SG fusion 
rather than full fusion of single SGs, under both basal and stimulating conditions. These findings 
contrast to those on the β-cell, for which different types of fusion events occur during different 
phases of secretion (21-26, 28, 29). Hence, approximately half of 1
st
 phase insulin secretion is 
mediated by predocked SGs undergoing full fusion (46). In contrast, the sustained, 2
nd
 phase of 
insulin exocytosis is largely determined by influx of newcomer SGs from the intracellular 
reserve pool which then undergo mostly full fusion, with only a small contribution attributed to 
compound exocytosis (24, 28). It is important to note that the use of 2-photon microscopy in the 
present study precluded determination of any contribution of kiss-and-run exocytosis to GLP-1 
secretion, as well as to whether the detected SGs were pre-docked or newcomer, which would be 
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better observed by total internal reflection fluorescence and electron microscopy. Furthermore, 
deletion of syn1a from the plasma membrane prevented not only single but also multi-granular 
fusion events. Indeed, compound fusion may require other isoforms of syn that are expressed in 
the L-cell (31), as demonstrated for the β-cell (23, 47). However, it is expected that prevention of 
initial SG fusion with the plasma membrane would preclude detection by 2-photon microscopy 
of any subsequent SG-to-SG interactions, including not only compound but also sequential 
fusion events. Thus, the factors that determine the exact nature of exocytotic fusion events in the 
L-cell remain to be fully defined. However, one signaling pathway that may be involved is 
Cdc42-dependent reorganization of the actin cytoskeleton that forms a permissive barrier to 
GLP-1 secretion (48) and which, therefore, may decrease the ability of SGs to move towards the 
plasma membrane. As a similar mechanism mediates glucose-stimulated exocytosis of 
newcomer SGs in the β-cell (49, 50), future studies to interrogate the relationships between 
Cdc42, the actin cytoskeleton and SG dynamics in the intestinal L-cell are warranted. 
Furthermore, altered β-cell SNARE protein expression in response to gluco- and lipotoxicity is 
known to affect insulin secretion (51, 52). However, although GLP-1 release is also dysregulated 
during feeding of a high-fat or Western diet and in association with hyperglycemia caused by 
circadian disruption (53-55), it currently remains unknown as to whether this is due to changes in 
expression of syn1a and/or other L-cell SNARE proteins.    
Single-cell imaging indicated that GLP-1 secretion by the primary L-cell is biphasic, with 
the 1
st
 phase occurring 1-6 min after stimulation, and a more sustained 2
nd
 phase at 7-12 min. 
Interestingly, the isolated rat ileum has previously been noted to demonstrate biphasic release of 
GLP-1 in response to bethanechol and bombesin, but not calcitonin-gene related peptide, with a 
1
st
 peak at 2-4 min and a 2
nd
 phase that is maintained for the duration of the vascular perfusion 
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(10). Furthermore, re-examination of total internal reflection fluorescence microscopy data from 
the GLUTag L-cell line also suggests the existence of two phases of exocytosis. Hence, ~0.4 
fusions/100 µm
2
-30 sec were detected under basal conditions, and this increased to ~1.5 at 1-3 
min after KCl-mediated depolarization, followed by a second phase with ~1 event/100 µm
2
-30 
sec over the ensuing 4-7 min (31).  Thus, unlike the β-cell, for which KCl-induced depolarization 
increases 1
st
 phase secretion, whereas glucose induces biphasic release (21-26, 28, 29), the 
intestinal L-cell demonstrates biphasic secretion following activation by KCl, forskolin and 
some, but not all, physiological secretagogues.  
 As compared to the normal intestine, wherein L-cells constitute ~0.5% of epithelial cells 
(56), 1.1% of the cells in the AMIC cultures were found to express GLP-1, indicating a relative 
enrichment in this ileal crypt-cell model. Furthermore, 100% of the AMIC L-cells were found to 
express syn1a and, of the syntaxin isoforms known to be expressed on the plasma membrane 
(Stx1a, -1b, -2, -3, -4; (42)), only Stx1a was found to be enriched. Consistent with an important 
role for this core SNARE protein in the L-cell, KO of syn1a reduced forskolin-stimulated GLP-1 
secretion at both the single-cell and population level in AMIC cultures, and reduced OGTT-
induced GLP-1 release in the mouse in vivo. While no profound effects of the KO were found on 
basal GLP-1 release in the ex vivo and single-cell models examined, basal GLP-1 levels were 
reduced in vivo as a potential consequence of villin-driven cre expression, resulting in altered 
release of or responsiveness to paracrine regulators of GLP-1 secretion. Of note, IE-syn1a KO 
animals demonstrated even greater reductions in basal- and stimulated GIP secretion, likely 
contributing to the glucose intolerant phenotype through both the reduction of its own 
insulinotropic actions and via reduced L-cell stimulation by GIP (11). Future studies examining 
exocytotic dynamics in the GIP-producing K-cell are clearly warranted. Finally, the maintenance 
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of basal L-cell exocytosis and only partial loss of 1
st
 phase of secretion in the absence of syn1a 
could suggest contributions by another syn isoform in the L-cell to mediate fusion of pre-docked 
SGs, with the almost complete loss of 2
nd
 phase secretion explained by the loss of syn1a-
mediated newcomer SG fusion, comparable to findings in the β-cell (47). Nonetheless, our 
previous report of expression of VAMP2 in primary L-cells, a role for VAMP2 in GLP-1 release, 
and an interaction between VAMP2, syn1a and SNAP25 in the GLUTag cells (31) is consistent 
with the notion that these proteins form a core SNARE complex in the primary intestinal L-cell.  
 Although both of the syn1a KO models used in this study were generated from villin-
creER
T2+/0
 and syn1a
fl/fl
 mice, small differences were noted in the IE-syn1a KO mice as 
compared those crossed with the Gcg-Venus animals. Hence, the IE-syn1a KO mice 
demonstrated increases in Stx1b and Stx2 expression. Conversely, the Venus-IE-syn1a KO 
exhibited an increase only in Gcg expression, which could reflect a potential effect of 
proglucagon-driven Venus expression in the L-cell. However, the subtle differences in gene 
expression between the KO models was presumed not to influence GLP-1 secretion, as L-cell 
secretion was found to be impaired by loss of syn1a in both the ex vivo secretion assays (IE-
syn1a KO) and single-cell experiments (Venus-IE-syn1a KO). Furthermore, when taken with the 
rigorous inclusion of multiple genotypes as controls for each of these animal models, our finding 
of consistent effects of syn1a KO to reduce GLP-1 secretion suggests that these small differences 
in the mouse models had no impact on the conclusions of this study.  
Interestingly, while both male and female animals displayed significantly reduced GLP-1 
and GIP levels, IE-syn1a KO mice demonstrated sexual dimorphism in their metabolic responses 
to oral glucose administration; similar differences in glucose tolerance were also found in the 
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Venus-IE-syn1a KO animals. The female animals therefore demonstrated an improved capacity 
to compensate for the reduction in the incretin hormones. However, whether these findings can 
be extrapolated to humans remains unclear, as a previous study has indicated that OGTT-induced 
changes in the levels of glucose, insulin and both of the incretin hormones are all increased in 
women (57). 
The mechanisms underlying GLP-1 release from the intestinal L-cell are of increasing 
interest as a therapeutic approach to the treatment of hyperglycemia in patients with T2D, either 
alone or in combination with DPP IV inhibition (5-7). Our findings identify an exquisite 
mechanism of metered secretory output that precisely regulates release of the incretin, GLP-1 
and, hence, insulin secretion following a meal. Furthermore, as the intestinal L-cell co-secretes a 
number of other biologically active peptide hormones, these findings may also have implications 
in other disease states. The demonstration of a role for syn1a in modulating stimulated SG fusion 
events provides impetus for further studies to elucidate the full complement of SNARE and 
cognate accessory proteins in the primary L-cell that mediate distinct exocytotic events, as well 
as their coupling to the diverse signaling pathways that are activated by nutrient ingestion. 
Elucidation of the exact mechanisms underlying GLP-1 release holds important implications for 
development of GLP-1 secretagogues to treat patients with T2D or obesity.  
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Figure Legends  
Figure 1: Primary murine intestinal L-cells express syn1a and secrete GLP-1 in vitro. (A-D) 
Mouse intestine (A) and AMIC cultures (B-C) were immunostained for GLP-1 (red) and syn1a 
(green); DAPI is blue, negative controls are shown in the inset, and arrows indicate GLP-1-
positive cells. Representative images are shown from n=6 IE-syn1a control (A-B) mice, and 
from n=4 IE-syn1a KO animals (C). Quantification of control and IE-syn1a KO AMIC L-cell 
syntaxin-1a immunofluorescence intensity (D; n=4 cells from 4 control mice and n=6 cells from 
5 IE-syn1a KO mice). (E-H) AMIC cultures from C57Bl/6 mice were treated for 2hr with 
forskolin/IBMX (E-F; n=10-11), or varying concentrations of GIP (G; n=7-12) or OEA (H; n=5-
7) with forskolin as the positive control. GLP-1 secretion as a percent of total content and total 
GLP-1 content for the same cultures are shown in (E-F), respectively. * p<0.05, ** p<0.01 and 
*** p<0.001 vs. vehicle control. 
 
Figure 2: IE-syn1a KO mice demonstrate small intestinal adaptive responses. (A-C) Body weight 
(A), small intestinal weight (B), and small intestinal weight normalized to body weight (C) in 
male and female control and IE-syn1a KO mice (n= 10-13). (D) Crypt depth and villus height in 
control and IE-syn1a KO mice (n=5-8). (E-F) Stx1a (E) and Stx isoform and Gcg (F) transcript 
levels in ileal mucosal scrapes from control and IE-syn1a-KO mice (n=10-13). * p<0.05, ** 
p<0.01 and *** p<0.001 vs. control mice. 
 
Figure 3: IE-syn1a KO mice demonstrate reduced GLP-1 secretory responses during an OGTT in 
association with impaired glucose tolerance. (A-E) Male and female control and IE-syn1a KO 
mice (n=8-22) were administered an OGTT at t=0 min followed by blood sampling at 0, 10, 60, 
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90 and 120 min; a second cohort of mice (n=7-10) also included sampling for blood glucose at t 
= 30 and 45 min. Blood glucose (A), glycemic area-under-the-curve (AUC, B) and levels of 
plasma insulin (C), GLP-1 (D; plasma GLP-1 levels were normalized to control levels at t=0 min 
(20.8 ± 3.1 pg/ml; n=25) to account for variance found between two different assay plates) and 
GIP (E). (F) Separate cohorts of male and female mice (n=6) were administered an IPGTT at t=0 
min followed by blood sampling for determination of blood glucose. * p<0.05, ** p<0.01 and 
*** p<0.001 vs. control mice or as indicated for the delta response. 
 
Figure 4: AMIC cultures from IE-syn1a KO mice demonstrate reduced GLP-1 secretory 
responses. (A-B) Stx1a (A) and Stx isoform and Gcg (B) transcript levels in AMIC cultures from 
male and female control and IE-syn1a KO mice (n=4-6). (C-D) Control and IE-syn1a KO AMIC 
cultures were treated for 2 hr with vehicle (basal) or forskolin plus IBMX (n=7-9), followed by 
determination of GLP-1 release into the media (C; control basal secretion was 5.9 ± 2.2% of total 
cell content) and (D) GLP-1 content in the media plus cells. ** p<0.01 and *** p<0.001 vs. 
basal; ### p<0.001 vs. same treatment in controls.             
                                                                                                                  
Figure 5: Venus-IE-syn1a KO mice demonstrate impaired glucose tolerance during an OGTT. 
(A-C) Body weight (A), small intestinal weight (B) and small intestinal weight normalized to 
body weight (C) in male and female control and IE-syn1a-KO mice. (D-E) mRNA transcript 
levels for Stx1a (D) and Stx isoforms and Gcg (E) in ileal mucosal scrapes from control and IE-
syn1a-KO mice. (F) Control and IE-syn1a KO mice were administered an OGTT at t=0 min 
followed by blood sampling for determination of blood glucose levels (n=9-12 for A-F). (G) 
RNAseq for syntaxin isoforms in FACS-isolated Venus
+
 vs. Venus
-
 jejunal/ileal epithelial cells 
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from female Gcg-Venus mice (inset shows expanded scale; n=3). FPKM, fragments per kilobase 
of exon per million fragments mapped. 
 
Figure 6: 2-Photon microscopy of primary ileal L-cells demonstrates the role of syn1a in 
multiple forms of exocytosis. (A) Representative images and fluorescent intensity tracings of 
single/full SG and multi-granular/compound SG fusion events in Venus-positive L-cells from 
control mice. (B-E) Quantification of the total number of fusion events collected over a 3 min 
basal period and a 12 min forskolin infusion period in control (B) and Venus-IE-syn1a KO (C) 
mice; (D) indicates the same data binned into different phases of secretion (basal: t = -3 to -1 
min; 1
st
 phase: t = 1 to 6 min; and 2
nd
 phase: t = 7 to 12 min) and then classified as full vs. 
compound fusion. The dotted line in (B) indicates best-fit curve for stimulated exocytosis (R
2
 = 
0.82). *p<0.05, ** p<0.01 and *** p<0.001 vs. basal; # p<0.05 and ### p<0.001 vs. the same 
phase in control mice, for total fusion events. (E) Cumulative total fusion events. * p<0.05, ** 
p<0.01 for each time point at t = 4-12 min. n= 9 cells from 6 control mice and 6 cells from 3 IE-
Venus-syn1a KO. 
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SUPPLEMENTAL TABLES 
Table S1: Genotyping primers  
Gene Forward Reverse Amplicon 
(bp) 
Annealing 
Temperature 
(
O 
C) 
Stx1a  GCT GCA GAA GCA 
AGA GAA CC 
CAG CCA TAC AAA 
AAC CAC CA 
WT: 404 
Flox: 239 
50.0 
Cre CAA GCC TGG CTC 
GAC GGC C 
CGC GAA CAT CTT 
CAG GTT CT 
390 50.0 
Gcg/GFP AAT TGA GCT CAT 
TTG GAC TGC C 
CTT GCC GTA GGT 
GGC ATC G 
210 50.0 
GFP/GFP CTG GTA GTG GTC 
GGC GAG C 
GTT CAG CGT GTC 
CGG CGA G 
470 
 
50.0 
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Table S2: Antibody table  
Sample  Antigen  Primary Antiserum Secondary Antiserum 
 
Ileal Tissue 
Syntaxin1a Rabbit anti-syn1a, 1:500 
(Abcam cat#41453) 
AlexaFluor488-goat anti-rabbit 
IgG, 1:150 (Life Technologies) 
GLP-1 Mouse anti-GLP-1, 1:400 
(Abcam cat # 23472) 
AlexaFluro555-goat anti-mouse 
IgG, 1:150 (Life Technologies) 
 
AMIC 
Culture 
Syntaxin1a Rabbit anti-syn1a, 1:1000 
(Abcam cat#41453) 
AlexaFluor488-goat anti-rabbit 
IgG, 1:150 (Life Technologies) 
GLP-1 Mouse anti-GLP-1, 1:200 
(Abcam cat # 23472) 
AlexaFluro555-goat anti-mouse 
IgG, 1:150 (Life Technologies) 
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Table S3: qRT-PCR Primer/Probes (all from Applied Biosystems)  
Transcript Product number Exons targeted 
Gcg Mm00801714_m1 5-6 
H3f3a  Mm01612808_g1 3-4 
Stx1a Mm00444008_m1 1-2 
Stx1b Mm01275274_m1 1-2 
Stx2 Mm04229900_m1 2-3 
Stx3 Mm01197689_m1 6-7 
Stx4 Mm00436827_m1 5-6 
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SUPPLEMENTAL FIGURE AND VIDEO LEGENDS 
Figure S1: Body weight (A), intestinal weight (B) and intestinal weight normalized to body 
weight (C) in the male vs. female control and IE-syn1a KO mice shown in Figure 2. 
 
Figure S2: Blood glucose (A), and plasma insulin (B) levels in the male vs. female control and 
IE-syn1a KO mice shown in Figure 3.  
 
Figure S3: Plasma GLP-1 (A), and GIP (B) levels in the male vs. female control and IE-syn1a 
KO mice shown in Figure 3.  
 
Figure S4: (A-B) Male C57Bl/6 mice were administered ileal AdV-RFP (control) or AdV-iCre 
followed by intra-ileal administration of OEA 2 d later, and determination of mucosal Stx1a 
mRNA transcript levels (A) and plasma GLP-1 levels (B; n=3-4). (C-D) AMIC cultures from 
male C57Bl/6 mice were treated with AdV-RFP (control) or AdV-iCre for 2 d, followed by 2 hr 
treatment with vehicle (basal), forskolin plus IBMX or OEA for 2 hr, and determination of cell 
Stx1a mRNA transcript levels (C) and GLP-1 content in the media and cells (D; n=4).   
 
Figure S5: Body weight (A), intestinal weight (B) and intestinal weight normalized to body 
weight (C) in the male vs. female control and Venus-IE-syn1a-KO mice shown in Figure 5. 
 
Figure S6: Blood glucose levels in the male vs. female control and Venus-IE-syn1a KO mice 
shown in Figure 5. 
 
Figure S7: Representative 2-photon images of full and compound fusion events using SRB (red) 
and Venus (green), as visualized in the respective cells shown in Figure 6A. 
 
Supplemental Video 1: Full-field view of a Venus
+
 L-cell (green) surrounded by unlabelled cells. 
Forskolin was added at t = 30 sec. Note the large granule size and multiple fusion events 
occurring in a single neighbouring cell (arrow), consistent with the known properties of mast 
cells. The same video is submitted in both .avi and .mp4 format. 
 
Supplemental Video 2: Single granule, full fusion event at t = 577.8 sec in the membrane of a 
Venus
+
 L-cell. The same video is submitted in both .avi and .mp4 format. 
 
Supplemental Video 3:  Multi-granular, compound fusion event at t = 129.3 – 255.3 sec in the 
membrane of a Venus
+
 L-cell. The same video is submitted in both .avi and .mp4 format. 
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Abstract  
Exocytosis of the hormone, glucagon-like peptide-1 (GLP-1), by the intestinal L-cell is 
essential for the incretin effect after nutrient ingestion, and is critical for the actions of 
dipeptidylpeptidase IV inhibitors that enhance GLP-1 levels in patients with type 2 diabetes. 2-
Photon microscopy revealed that exocytosis of GLP-1 is biphasic, with a 1
st
 peak at 1-6min and a 
2
nd
 peak at 7-12min after stimulation with forskolin. Approximately 75% of the exocytotic 
events were represented by compound granule fusion, and the remainder were accounted for by 
full fusion of single granules, under basal and stimulated conditions. The core SNARE protein, 
syntaxin-1a (syn1a), was expressed by murine ileal L-cells. At the single L-cell level, 1
st
 phase 
forskolin-induced exocytosis was reduced to basal (p<0.05) and 2
nd
 phase exocytosis was 
abolished (p<0.05) by syn1a knockout. L-cells from intestinal-epithelial syn1a-deficient mice 
demonstrated a 63% reduction in forskolin-induced GLP-1 release in vitro (p<0.001), and a 23% 
reduction in oral glucose-stimulated GLP-1 secretion (p<0.05) in association with impairments in 
glucose-stimulated insulin release (by 60%, p<0.01) and glucose tolerance (by 20%, p<0.01). 
Our findings therefore identify an exquisite mechanism of metered secretory output that 
precisely regulates release of the incretin hormone, GLP-1 and, hence, insulin secretion 
following a meal. 
 
Keywords: 2-photon microscopy, exocytosis, GIP, GLP-1, GLP-2, intestine, knockout, OGTT, 
oxyntomodulin, primary cells, proglucagon-Venus, secretion, villin-cre 
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Introduction 
The incretin hormone, glucagon-like peptide-1 (GLP-1), plays an essential role in the 
maintenance of normoglycemia, through enhancement of glucose-dependent insulin secretion 
and suppression of glucagon release, gastric emptying and appetite (1, 2). As a consequence of 
these beneficial actions, GLP-1 receptor agonists are now widely-utilized to treat patients with 
type 2 diabetes (T2D) and obesity. In contrast to the actions of GLP-1-derivative drugs, 
therapeutic dipeptidylpeptidase IV (DPP IV) inhibitors prevent the degradation of endogenously-
secreted GLP-1, as well as of the other incretin hormone, glucose-dependent insulinotropic 
peptide (GIP) (3, 4). The possibility of utilizing GLP-1 secretagogues, alone or in combination 
with DPP IV inhibition, has therefore engendered considerable interest as a new approach to 
incretin therapy (5-7).   
GLP-1Hormone secretion by the intestinal L-cell which includes, not only GLP-1 but 
also the related peptides, GLP-2 and oxyntomodulin, demonstrates two peaks of release 
following nutrient ingestion (8, 9). Rodent studies have demonstrated that part of the early peak 
of GLP-1 secretion is mediated indirectly, through vagal pathways originating in the duodenum 
that activate muscarinic receptors on the distal L-cell (10-12). In contrast, the later peak of GLP-
1 release is initiated by direct contact of luminal nutrients with the L-cell, resulting in 
transporter- and ion channel-mediated depolarization, as well as activation of multiple G protein-
coupled receptors (13-16). Many of these receptors are expressed not only by the intestinal L-
cell, but also by the pancreatic β-cell (17), consistent with the coordinated release of GLP-1 and 
insulin in vivo.  However, in contrast to the β-cell, for which the signaling pathways regulating 
insulin secretion are well-established (18), much less is known about the intestinal L-cell.  
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Glucose-mediated depolarization of the β-cell opens voltage-gated calcium channels, 
thereby activating the calcium-sensor, synaptotagmin-7 (19). This relieves the clamping action of 
synaptogamin-7 on the SNARE fusion machinery, which consists of the vesicle SNARE protein, 
VAMP, and the plasma membrane SNAREs, syntaxin (syn) and SNAP23/25 (20), thus 
permitting insulin exocytosis. Although the β-cell expresses several SNARE isoforms, VAMP2 
and syn1a are most important for 1
st
 phase glucose-stimulated insulin secretion (GSIS), with 
VAMP8 and syn3/4 contributing to both 1
st
 and 2
nd
 phase release (21-23). The SNARE proteins 
also mediate several different types of exocytotic events in the β-cell. Thus, predocked secretory 
granules (SGs) contribute predominantly to 1
st
 phase secretion, whereas newcomer granules 
recruited from an intracellular reserve pool account for some of 1
st
 phase and practically all of 
2
nd
 phase insulin exocytosis (24). Furthermore, these SGs also undergo temporally and 
physically distinct types of fusion with the plasma membrane, termed full, sequential, compound 
and kiss-and-run (24-29).  
While one study has demonstrated a role for synaptotagmin-7 in GLP-1 secretion (30), 
little is known about the role of the core SNARE proteins in the L-cell. We have reported that the 
murine GLUTag L-cell line expresses multiple isoforms of VAMP and syn, as well as SNAP25 
(31). VAMP2 was demonstrated to play an essential important role in GLP-1 secretion by these 
cells, and was also found to be expressed in primary mouse intestinal L-cells. Furthermore, 
VAMP2 co-immunoprecipitates with syn1a and SNAP25 in the GLUTag cells, suggesting these 
SNARE proteins form a functional exocytotic complex in the L-cell. Given the current interest in 
therapeutic approaches to enhance release of GLP-1 into the circulation (5-7), we have now 
utilized novel knockout mouse models in vivo and ex vivo, in combination with single-cell 
visualization of exocytosis, to interrogate GLP-1 release by the primary intestinal L-cell. We 
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show that GLP-1 release is biphasic, as mediated primarily by multi-granular (i.e. compound) 
fusion under both basal and stimulated conditions, and that the SNARE protein, syn1a, plays an 
essential role in the exocytosis of GLP-1. These findings identify novel regulatory mechanisms 
that underlie secretion of the incretin hormone, GLP-1, and have implications to the development 
of GLP-1 secretagogues for therapeutic use in the treatment of T2D and obesity.  
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Methods 
Animals Male C57Bl/6 mice (7-12 wk) were from Charles River. Female syn1a
fl/fl
 (32) were 
crossed with male villin-creER
T2+/0
 (B6-Tg(Vil-cre/ERT2)23Syr) (33, 34) mice and the resultant 
tamoxifen-inducible intestinal-epithelial syn1a
fl/fl
;villin-creER
T2+/0
 (IE-syn1a KO) animals were 
crossed with proglucagon (Gcg)-Venus mice (35) to generate Venus-IE-syn1a KO animals (see 
Table S1 for primers).  Age- (7-12 wk) and sex-matched male and female littermates were 
studied, and controls included: vehicle- and tamoxifen (1 mg/100 µl sunflower oil, ip for 5 d)-
treated syn1a
fl/fl
, villin-creER
T2+/0
, syn1a
fl/-
;villin-creER
T2+/0
 and syn1a
fl/-
;villin-creER
T2+/0
;Gcg-
Venus mice, as well as vehicle-treated syn1a
fl/fl
;villin-creER
T2+/0
 and syn1a
fl/fl
;villin-
creER
T2+/0
;Gcg-Venus animals, as appropriate for the KO model being studied. Two-three days 
after induction, mice were fasted overnight followed by an oral or intraperitoneal glucose 
tolerance test (OGTT: 5g/kg glucose; as previously shown to optimize GLP-1 release in mice 
(36); and IPGTT: 3 g/kg glucose, as determined in pilot studies to match the glycemic response 
observed in the OGTT, data not shown) and tail-vein blood collection. Glycemia was determined 
using a glucose meter (OneTouch, LifeScan), and plasma total GLP-1 (Mesoscale Discovery), 
total GIP (Millipore) and  insulin (Crystal Chem) by kit-assay, as reported (37). Due to their high 
concentration of L-cells (38), ileal segments were collected for primary culture and analyses. All 
animal protocols were approved by the Animal Care Committee of the University of Toronto.  
Adult mouse ileal crypt (AMIC) cultures Isolated crypts from 10-cm mouse ileum were plated 
overnight, as reported (35). Two-hr secretion assays were followed by ELISA (Millipore) for 
active GLP-1 levels in media and cells, as reported (12, 35). Secretion was calculated as the 
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percent of total culture content that was detected in the media. Experiments were conducted in 
quadruplicate wells to make n=1 per mouse. 
2-Photon microscopy was performed on AMIC cultures perfused at 2 ml/min and 30 
o
C. 
Sulforhodamine-B (0.8 mM) (25) was added 2-3 min prior to visualization using a Nikon A1R 
multi-photon microscope, for up to 3 min (basal) followed by 12 min with 50 µM forskolin. L-
cells were identified by Venus (YFP) fluorescence, and the cell membrane was defined by the 
extracellular localization of sulforhodamine-B. Data were analysed with NIS-Elements software 
(Nikon). Focal events that occurred over ≤10 sec were classified as full fusion, whereas events of 
longer duration were considered to be compound fusion.  
Morphometric and immunometric analyses Crypt-villus height was measured in hematoxylin & 
eosin-stained ileal sections in a minimum of 20 well-oriented axes per mouse. Ileal sections and 
AMIC cultures were stained for syn1a and GLP-1 (see Table S2 for antibodies), followed by 
visualization using a Zeiss deconvolution microscope and analysis of fluorescence intensity 
using ImageJ# (39). Negative controls omitted the primary antisera. 
Molecular analyses Ileal Venus
+
 and Venus
-
 cells were collected from female Gcg-Venus mice 
(n=3) by fluorescence-activated cell sorting. Barcode-ligation and end repair were achieved 
using the Ovation Rapid DR Multiplex System 1–96 (NuGEN). Combined barcoded libraries 
underwent SE50 sequencing using an Illumina HiSeq 2500 system (Genomics Core Facility, 
Cancer Research UK Cambridge Institute). Sequence reads were demultiplexed using the Casava 
pipeline (Illumina) and aligned to the mouse genome (GRCm38) using Tophat-v2.1.0 
(http://ccb.jhu.edu/software/tophat/index.shtml). Differential gene expression was determined 
using Cufflinks-v2.2.1 (http://cole-trapnell-lab.github.io/cufflinks/), as reported (35).  
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Total RNA from ileal mucosal scrapes and AMIC cultures was reverse-transcribed and 
analyzed by PCR with primer/probe sets from Applied Biosystems (Table S3). Histone 3A was 
used as the internal control for analysis by the ∆∆Ct method.  
Adenovirus studies: Syn1a
fl/fl
 mice were anesthetized, laparotomized and 0.75 ml of 0.9-1.8x10
8
 
infection units/ml Adenovirus-RFP-improved cre-recombinase (Adv-iCre) or Adv-RFP (control; 
Vector Biolabs) was injected into the distal ileal lumen. Animals recovered for 2d and were then 
re-laparotomized and 0.75 ml oleoylethanolamide (OEA; 15 µM) was injected into the ileum 
followed by sampling for analysis of glycemia, plasma hormone levels and ileal gene expression, 
as above.  
AMIC cultures were infected with 2.4x10
7
 IFU/ml Adv-iCre or Adv-RFP for 48 hr, 
followed by a 2 hr GLP-1 secretion assay and analysis by ELISA and qRT-PCR, as above. 
Statistical Analyses Data are shown as mean ± SEM. Statistical differences were determined by 
Student’s t test or 1- or 2-way ANOVA followed by Student’s t test or Tukey multiple 
comparison test, as appropriate.  
  
Page 54 of 79
For Peer Review Only
Diabetes
9 
 
Results 
Immunostaining of the ileum from normal mice revealed expression of syn1a in GLP-1-
expressing cells, as well as in other cells in the crypt and scattered through the villous epithelium 
(Figure 1A).  We also examined co-localization of GLP-1 and syn1a in AMIC cultures, a 
valuable ex vivo model for the study of GLP-1 secretion by primary L-cells (35) (Figure 1B). 
Importantly, of the 1.1 ± 0.1% of all AMIC cells that were GLP-1-positive (n=1670-5095 cells 
each in 6 independent cultures), 100% were found to co-express syn1a. Confirming specificity of 
the syn1a staining, AMIC cultures generated from intestinal-epithelial syn1a knockout (IE-syn1a 
KO) mice demonstrated a significant loss of syn1a staining in the L-cells (p<0.001) as well as 
more globally in other, unidentified crypt cells (Figure 1C-D).  
GLP-1 secretion by AMIC cultures from normal mice was increased to 2.3-fold of 
control (p<0.01) in response to treatment with forskolin plus 3-isobutyl-1-methylxanthine 
(IBMX), without any change in GLP-1 synthesis (Figures 1E-F). Similarly, treatment with the 
physiological secretagogues, GIP (Figure 1G) and the GPR119 agonist, oleoylethanolamide 
(OEA; Figure 1H) enhanced GLP-1 release, to 1.7- and 3.5-fold of control (p<0.05-0.001), 
respectively. These findings suggest a role for syn1a in L-cell secretion and support use of both 
the IE-syn1a KO mouse model and AMIC cultures in further studies to assess this hypothesis.  
Compared to control animals, IE-syn1a KO mice demonstrated increases in body (Figure 
2A) and intestinal (Figure 2B) weight 7-12 days following the completion of daily tamoxifen 
injections (p<0.05-0.001). However, upon normalization of intestinal weight to body weight, the 
observed increase in intestinal weight was maintained only in male animals lacking syn1a 
(Figures 2C and S1), suggestive of sexual dimorphism. Morphologic characterization of the 
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intestinal epithelium further revealed that IE-syn1a KO animals had a small but significant 
increase in crypt depth (p<0.01; Figure 2D). Furthermore, the 39% reduction of syn1a (i.e. 
Stx1a) mRNA observed in intestinal mucosal scrapes from KO animals (p<0.05; Figure 2E) was 
associated with increases in the expression of Stx1b and -2 (p<0.05-0.01; Figure 2F). While the 
function of syn1b in the intestinal epithelium is not known, it appears to play a role in mast cell 
degranulation (40). In contrast, Stx2 (aka epimorphin) expression in mesenchymal cells abutting 
the epithelium has been shown to regulate the morphology of the crypt-to-villus axis (41), 
suggesting a role in the observed increase in crypt depth. Examination of two other syn isoforms 
that are also localized to the plasma membrane, Stx3 and -4  (42), did not reveal any other 
adaptive changes (Figure 2F).  
To determine whether intestinal-epithelial syn1a has any relationship to glucose 
tolerance, we performed an oral glucose tolerance test (OGTT) in control and IE-syn1a KO mice 
two-days following completion of tamoxifen or vehicle injection. IE-syn1a KO animals 
displayed a significant impairment in glucose tolerance, with blood glucose levels reaching 1.3- 
and 1.4-fold of controls at t=45 (p<0.05) and 60 min (p<0.001), respectively (Figure 3A). 
Accordingly, the 2-hr glycemic area-under-the-curve in IE-syn1aKO mice was also significantly 
increased, to 1.2-fold of controls (p<0.01; Figure 3B).  Consistent with this finding, IE-syn1a KO 
mice showed a reduction in plasma insulin levels as compared with controls, which reached 
statistical significance at t=60 min (Figure 3C). Comparison of the overall glycemic response to 
that of insulin indicated that GSIS in IE-syn1a KO animals was reduced by 60% vs. controls 
(p<0.05; Figure 3D). Furthermore, basal GLP-1 levels were 17% lower in IE-syn1a KO mice 
than in controls (p<0.05), with an even further reduction at t=10 min post-oral glucose 
administration (by 23%, p<0.05 vs. basal; p<0.01 vs. the difference at t=0 min; Figure 3D). 
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Analyzing these data for sexual dimorphism showed that male but not female IE-syn1a KO 
animals accounted for the glucose intolerance and reduced plasma insulin levels observed during 
the OGTT (Figure S2). However, plasma GLP-1 levels were consistently reduced in both male 
and female IE-syn1a KO animals (Figure S3A). Gene expression analysis of the GLP-1 
prohormone, proglucagon (Gcg), in the intestinal mucosa showed no difference between KO and 
control animals (Figure 2F), indicating that the reduced GLP-1 levels in IE-syn1a KO mice are 
not due to a deficiency in GLP-1 production. Similar to the reduction in GLP-1 levels, both male 
and female IE-syn1a KO animals also displayed significantly lower plasma GIP concentrations, 
by 31 - 53% at t=0, 10 and 60 min (p<0.05-0.01; Figures 3E and S3B). Furthermore, a 
requirement for the incretin hormones in the impaired glucose tolerance of KO animals was 
confirmed by the demonstration that mice with loss of intestinal-epithelial syn1a had normal 
glucose tolerance in response to an IPGTT (Figure 3F). Together, these data suggest that the 
compromised glucose homeostasis in IE-syn1a KO animals occurs, at least in part, as a result of 
reductions in both GLP-1 and GIP secretion.  
To confirm that loss of syn1a impairs L-cell secretory function, AMIC cultures were 
generated from crypts isolated from IE-syn1a KO and control animals. Interestingly, IE-syn1a 
KO AMIC cultures were found to have a 78% reduction in Stx1a expression (p<0.01; Figure 
4A). This more profound knock-down in the crypt cultures compared to the mucosal scrapes is 
likely a consequence of epithelial cell enrichment in the cultures, whereas both villus epithelial 
and non-villin-expressing syn1a-positive cells contribute to the syn1a signal in the scrapes. We 
also examined the Stx1b, -2, -3 and -4 isoforms in the AMIC cultures and found no differences in 
expression (Figure 4B), further suggesting that adaptive changes that were observed in the 
mucosa were independent of the intestinal-epithelial cells.   
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Secretion assays with AMIC cultures generated from IE-syn1a KO mice demonstrated no 
difference in basal GLP-1 secretion as compared to control animals (Figure 4C). However, IE-
syn1a KO mice displayed a 2.6-fold reduction in forskolin-stimulated GLP-1 secretion, to 37% 
of the response found in controls (p<0.001; Figure 4C). Total GLP-1 content of the cultured cells 
did not differ between the genotypes or treatment groups (Figure 4D). Gcg gene expression also 
did not differ as a result of loss of syn1a (Figure 4B), further suggesting that the reduced GLP-1 
secretion is a result of disrupted L-cell secretory function.  
To more directly examine the role of syn1a in GLP-1 secretion by the primary L-cell, we 
initially conducted in vivo and in vitro studies utilizing adenovirus-mediated knockdown of 
syn1a. However, application of the control adenovirus alone blunted the ability of the intestinal 
L-cells to respond to known secretagogues, making this an inappropriate model for further study 
(Figure S4). We therefore crossed the IE-syn1a KO animals with mice expressing Venus YFP 
under the control of the Gcg promoter (35) to permit identification of the L-cell for exocytotic 
analysis. While Venus-IE-syn1a KO mice did not show any changes in body weight, they were 
found to have increased intestinal weight which, following normalization to body weight, was 
maintained only in male animals lacking syn1a (Figures 5A-C and S5). This pattern was very 
similar to that observed in the IE-syn1a KO mice that did not express Gcg-Venus (Figure S1). 
Unexpectedly, as compared to the IE-syn1a KO animals, Venus-IE-syn1a KO mice did not show 
any changes in body or intestinal weight, and had no evidence of sexual dimorphism (Figures 
5A-C and S3). Furthermore, although Stx1a expression was reduced by 58% (p<0.05) in the 
intestinal mucosa (Figure 5D), there were no significant changes in expression of Stx1b and -2 
(Figure 5E). However, an OGTT revealed that Venus-IE-syn1a KO animals, like the IE-syn1a 
KO mice, had impaired glucose tolerance, with significantly elevated glycemia at t=60 min after 
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oral glucose administration in comparison to controls (1.3-fold of control values, p<0.05; Figure 
5F). Like the IE-syn1a KO mice, these animals also demonstrated sexual dimorphism, with 
significant changes found only in the male mice (Figure S6). Collectively, these findings 
suggested an impairment in GLP-1 secretion in the Venus-IE-syn1a KO animals, despite the 
finding of a 1.8-fold increase in intestinal mucosal Gcg gene expression (p<0.05; Figure 5D).    
As the heterogonous cell population of both the ileal mucosa and isolated ileal crypt 
cultures limits our understanding of L-cell specific gene expression, we compiled a syntaxin 
isoform expression profile from Venus-positive L-cells by RNAseq (Figure 5G). Of the four syn 
isoforms known to be localized on the plasma membrane, only Stx1a appeared to be enriched (by 
3.6-fold) in the Venus-positive L-cells as compared to Venus-negative intestinal-epithelial cells. 
Collectively, these data further suggest a role for syn1a in GLP-1 exocytosis, and validate the use 
of the Venus-IE-syn1a KO mice as a model for our studies.   
As exocytosis by the primary intestinal L-cell has not previously been described, we 
utilized 2-photon microscopy to visualize SG fusion events in Venus-positive L-cells from both 
control and Venus-IE-syn1a KO mice, under basal and 50 µM forskolin-stimulated conditions 
(Figures 6A and S7). In the absence of forskolin, all of the Venus-positive and some of the 
Venus-negative cells demonstrated periodic exocytotic events; an increase in exocytosis in both 
cell types was noted upon the addition of forskolin. However, interestingly, some cells 
demonstrated a profound level of activity as compared to the surrounding cells, with a large 
granule size that is consistent with the known characteristics of mast cells (Supplemental Video 
1) (43). As has been reported for the β-cell (24-29), distinct types of exocytotic events were 
observed in Venus-positive L-cells from control animals. Thus, throughout the duration of our 
recordings, we identified both single (full; Supplemental Video 2) and multi-granular 
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(compound; Supplemental Video 3) SG fusions that differed in the size of the signal and the 
duration of the event (Figure 6A).     
The pattern of fusion events observed in L-cells from Venus-control mice was strongly 
indicative of biphasic exocytosis. Hence, after the basal period, the addition of forskolin 
stimulated a 1
st
-phase of exocytosis at 1-6 min, followed by a 2
nd
 phase at 7-12 min (Figure 6B, 
D and E). In comparing single L-cells from Venus-IE-syn1a KO and Venus-control mice, there 
was no obvious change in the number of SG fusion events during the basal period (Figure 6B-E). 
However, recordings from Venus-IE-syn1a KO L-cells demonstrated that syn1a depletion 
dramatically reduced the number of SG fusion events under stimulating conditions, such that 1
st
 
phase exocytosis was reduced to basal levels (p<0.05) and 2
nd
 phase was abolished (p<0.05). 
Finally, determination of the contributions of full and compound fusion events to each phase of 
secretion revealed that L-cell exocytosis is largely mediated by compound fusion (approximately 
75% of total events), under both basal and stimulated conditions (Figure 6D). Importantly, in the 
absence of syn1a, the reduced number of SG fusion events in both 1
st
 and 2
nd
 phase secretion was 
attributed to the loss of both full and compound fusion. This result demonstrates the preservation 
of SG fusion competence under basal conditions but a requirement for syn1a in stimulated SG 
fusion in the primary L-cell. When taken together, these data illuminate the spatio-temporal 
activity of the SG exocytosis that underlies GLP-1 secretion.  
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Discussion  
The incretin actions of GLP-1The actions of the incretin hormones, GLP-1 and GIP, 
account for ~50% of the insulin response to nutrient ingestion (44, 45).  However, despite the 
importance of GLP-1 to glucose homeostasis, major gaps remain in our understanding of the 
molecular machinery that regulates GLP-1 release. Although studies on the primary L-cell have 
been limited in the past due, in large part, to the diffuse dispersion of these cells throughout the 
intestinal epithelium (38), recent advances now permit direct visualization of exocytosis by 
reporter-labelled L-cells ex vivo following primary culture (35). Using these approaches, the 
findings of the present study demonstrate the dynamics of SG fusion to the plasma membrane of 
the primary intestinal L-cell, and the essential role of the core SNARE protein, syn1a, in 
secretagogue-induced exocytosis of GLP-1.  
2-Photon microscopy demonstrated that exocytosis by the primary L-cell is mediated 
through different types of exocytotic events, of which the majority are compound SG fusion 
rather than full fusion of single SGs, under both basal and stimulating conditions. These findings 
contrast to those on the β-cell, for which different types of fusion events occur during different 
phases of secretion (21-26, 28, 29). Hence, approximately half of 1
st
 phase insulin secretion is 
mediated by predocked SGs undergoing full fusion (46). In contrast, the sustained, 2
nd
 phase of 
insulin exocytosis is largely determined by influx of newcomer SGs from the intracellular 
reserve pool which then undergo mostly full fusion, with only a small contribution attributed to 
compound exocytosis (24, 28). It is important to note that the use of 2-photon microscopy in the 
present study precluded determination of any contribution of kiss-and-run exocytosis to GLP-1 
secretion, as well as to whether the detected SGs were pre-docked or newcomer, which would be 
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better observed by total internal reflection fluorescence and electron microscopy. Furthermore, 
deletion of syn1a from the plasma membrane prevented not only single but also multi-granular 
fusion events. Indeed, compound fusion may require other isoforms of syn that are expressed in 
the L-cell (31), as demonstrated for the β-cell (23, 47). However, it is expected that prevention of 
initial SG fusion with the plasma membrane would preclude detection by 2-photon microscopy 
of any subsequent SG-to-SG interactions, including not only compound but also sequential 
fusion events. Thus, the factors that determine the exact nature of exocytotic fusion events in the 
L-cell remain to be fully defined. However, one signaling pathway that may be involved is 
Cdc42-dependent reorganization of the actin cytoskeleton that forms a permissive barrier to 
GLP-1 secretion (48) and which, therefore, may decrease the ability of SGs to move towards the 
plasma membrane. As a similar mechanism mediates glucose-stimulated exocytosis of 
newcomer SGs in the β-cell (49, 50), future studies to interrogate the relationships between 
Cdc42, the actin cytoskeleton and SG dynamics in the intestinal L-cell are warranted. 
Furthermore, altered β-cell SNARE protein expression in response to gluco- and lipotoxicity is 
known to affect insulin secretion (51, 52). However, although GLP-1 release is also dysregulated 
during feeding of a high-fat or Western diet and in association with hyperglycemia caused by 
circadian disruption (53-55), it currently remains unknown as to whether this is due to changes in 
expression of syn1a and/or other L-cell SNARE proteins.    
Single-cell imaging indicated that GLP-1 secretion by the primary L-cell is biphasic, with 
the 1
st
 phase occurring 1-6 min after stimulation, and a more sustained 2
nd
 phase at 7-12 min. 
Interestingly, the isolated rat ileum has previously been noted to demonstrate biphasic release of 
GLP-1 in response to bethanechol and bombesin, but not calcitonin-gene related peptide, with a 
1
st
 peak at 2-4 min and a 2
nd
 phase that is maintained for the duration of the vascular perfusion 
Page 62 of 79
For Peer Review Only
Diabetes
17 
 
(10). Furthermore, re-examination of total internal reflection fluorescence microscopy data from 
the GLUTag L-cell line also suggests the existence of two phases of exocytosis. Hence, ~0.4 
fusions/100 µm
2
-30 sec were detected under basal conditions, and this increased to ~1.5 at 1-3 
min after KCl-mediated depolarization, followed by a second phase with ~1 event/100 µm
2
-30 
sec over the ensuing 4-7 min (31).  Thus, unlike the β-cell, for which KCl-induced depolarization 
increases 1
st
 phase secretion, whereas glucose induces biphasic release (21-26, 28, 29), the 
intestinal L-cell demonstrates biphasic secretion following activation by KCl, forskolin and 
some, but not all, physiological secretagogues.  
 As compared to the normal intestine, wherein L-cells constitute ~0.5% of epithelial cells 
(56), 1.1% of the cells in the AMIC cultures were found to express GLP-1, indicating a relative 
enrichment in this ileal crypt-cell model. Furthermore, 100% of the AMIC L-cells were found to 
express syn1a and, of the syntaxin isoforms known to be expressed on the plasma membrane 
(Stx1a, -1b, -2, -3, -4; (42)), only Stx1a was found to be enriched. Consistent with an essential 
important role for this core SNARE protein in the L-cell, KO of syn1a reduced forskolin-
stimulated GLP-1 secretion at both the single-cell and population level in AMIC cultures, and 
reduced OGTT-induced GLP-1 release in the mouse in vivo. While no profound effects of the 
KO were found on basal GLP-1 release in the ex vivo and single-cell models examined, basal 
GLP-1 levels were reduced in vivo as a potential consequence of villin-driven cre expression, 
resulting in altered release of or responsiveness to paracrine regulators of GLP-1 secretion. Of 
note, IE-syn1a KO animals demonstrated even greater reductions in basal- and stimulated GIP 
secretion, likely contributing to the glucose intolerant phenotype through both the reduction of its 
own insulinotropic actions and via reduced L-cell stimulation by GIP (11). Future studies 
examining exocytotic dynamics in the GIP-producing K-cell are clearly warranted. majority of 
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the models examined, possible roles for other syntaxin isoforms in the L-cell cannot be 
discounted. Finally, the maintenance of basal L-cell exocytosis and only partial loss of 1
st
 phase 
of secretion in the absence of syn1a could suggest contributions by another syn isoform in the L-
cell to mediate fusion of pre-docked SGs, with the almost complete loss of 2
nd
 phase secretion 
explained by the loss of syn1a-mediated newcomer SG fusion, comparable to findings in the β-
cell (47). Nonetheless, our previous report of expression of VAMP2 in primary L-cells, a role for 
VAMP2 in GLP-1 release, and an interaction between VAMP2, syn1a and SNAP25 in the 
GLUTag cells (31) is consistent with the notion that these proteins form a core SNARE complex 
in the primary intestinal L-cell.  
 Although both of the syn1a KO models used in this study were generated from villin-
creER
T2+/0
 and syn1a
fl/fl
 mice, small differences were noted in the IE-syn1a KO mice as 
compared those crossed with the Gcg-Venus animals. Hence, the IE-syn1a KO mice 
demonstrated sexually-dimorphic increases in body and intestinal weight, slightly deeper crypts 
andincreases in Stx1b and Stx2 expression. Conversely, the Venus-IE-syn1a KO exhibited an 
increase only in Gcg expression, which could reflect a potential effect of proglucagon-driven 
Venus expression in the L-cell. However, the subtle differences in gene expression between the 
KO models was presumed not to influence GLP-1 secretion, as L-cell secretion was found to be 
impaired by loss of syn1a in both the ex vivo secretion assays (IE-syn1a KO) and single-cell 
experiments (Venus-IE-syn1a KO). Furthermore, when taken with the rigorous inclusion of 
multiple genotypes as controls for each of these animal models, our finding of consistent effects 
of syn1a KO to reduce GLP-1 secretion suggests that these small differences in the mouse 
models had no impact on the conclusions of this study.  
Page 64 of 79
For Peer Review Only
Diabetes
19 
 
Interestingly, while both male and female animals displayed significantly reduced GLP-1 
and GIP levels, IE-syn1a KO mice demonstrated sexual dimorphism in their metabolic responses 
to oral glucose administration; similar differences in glucose tolerance were also found in the 
Venus-IE-syn1a KO animals. The female animals therefore demonstrated an improved capacity 
to compensate for the reduction in the incretin hormones. However, whether these findings can 
be extrapolated to humans remains unclear, as a previous study has indicated that OGTT-induced 
changes in the levels of glucose, insulin and both of the incretin hormones are all increased in 
women (57). 
The mechanisms underlying GLP-1 release from the intestinal L-cell are of increasing 
interest as a therapeutic approach to the treatment of hyperglycemia in patients with T2D, either 
alone or in combination with DPP IV inhibition (5-7). Our findings identify an exquisite 
mechanism of metered secretory output that precisely regulates release of the incretin, GLP-1 
and, hence, insulin secretion following a meal. Furthermore, as the intestinal L-cell co-secretes a 
number of other biologically active peptide hormones, these findings may also have implications 
in other disease states. The demonstration of a role for syn1a in modulating stimulated SG fusion 
events provides impetus for further studies to elucidate the full complement of SNARE and 
cognate accessory proteins in the primary L-cell that mediate distinct exocytotic events, as well 
as their coupling to the diverse signaling pathways that are activated by nutrient ingestion. 
Elucidation of the exact mechanisms underlying GLP-1 release holds important implications for 
development of GLP-1 secretagogues to treat patients with T2D or obesity.  
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Figure Legends  
Figure 1: Primary murine intestinal L-cells express syn1a and secrete GLP-1 in vitro. (A-D) 
Mouse intestine (A) and AMIC cultures (B-C) were immunostained for GLP-1 (red) and syn1a 
(green); DAPI is blue, negative controls are shown in the inset, and arrows indicate GLP-1-
positive cells. Representative images are shown from n=6 IE-syn1a control (A-B) mice, and 
from n=4 IE-syn1a KO animals (C). Quantification of control and IE-syn1a KO AMIC L-cell 
syntaxin-1a immunofluorescence intensity (D; n=4 cells from 4 control mice and n=6 cells from 
5 IE-syn1a KO mice). (E-H) AMIC cultures from C57Bl/6 mice were treated for 2hr with 
forskolin/IBMX (E-F; n=10-11), or varying concentrations of GIP (G; n=7-12) or OEA (H; n=5-
7) with forskolin as the positive control. GLP-1 secretion as a percent of total content and total 
GLP-1 content for the same cultures are shown in (E-F), respectively. * p<0.05, ** p<0.01 and 
*** p<0.001 vs. vehicle control. 
 
Figure 2: IE-syn1a KO mice demonstrate small intestinal adaptive responses. (A-C) Body weight 
(A), small intestinal weight (B), and small intestinal weight normalized to body weight (C) in 
male and female control and IE-syn1a KO mice (n= 10-13). (D) Crypt-Crypt depth and villus 
height in control and IE-syn1a KO mice (n=5-8). (E-F) Stx1a (E) and Stx isoform and Gcg (F) 
transcript levels in ileal mucosal scrapes from control and IE-syn1a-KO mice (n=10-13). * 
p<0.05, ** p<0.01 and *** p<0.001 vs. control mice. 
 
Figure 3: IE-syn1a KO mice demonstrate reduced GLP-1 secretory responses during an OGTT in 
association with impaired glucose tolerance. (A-E) Male and female control and IE-syn1a KO 
mice (n=8-22) were administered an OGTT at t=0 min followed by blood sampling at 0, 10, 60, 
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90 and 120 min; a second cohort of mice (n=7-10) also included sampling for blood glucose at t 
= 30 and 45 min. for determination of Blood glucose (A), glycemic area-under-the-curve (AUC, 
B) and plasma insulin (C), the ratio of the glucose to insulin response GLP-1 (D; plasma GLP-1 
levels were normalized to control levels at t=0 min (20.8 ± 3.1 pg/ml; n=25) to account for 
variance found between two different assay plates) and GIP (E). and plasma GLP-1 levels (E). 
(F) Separate cohorts of male and female mice (n=6) were administered an IPGTT at t=0 min 
followed by blood sampling for determination of blood glucose. * p<0.05, ** p<0.01 and *** 
p<0.001 vs. control mice or as indicated for the delta response. 
 
Figure 4: AMIC cultures from IE-syn1a KO mice demonstrate reduced GLP-1 secretory 
responses. (A-B) Stx1a (A) and Stx isoform and Gcg (B) transcript levels in AMIC cultures from 
male and female control and IE-syn1a KO mice (n=4-6). (C-D) Control and IE-syn1a KO AMIC 
cultures were treated for 2 hr with vehicle (basal) or forskolin plus IBMX (n=7-9), followed by 
determination of GLP-1 release into the media (C; control basal secretion was 5.9 ± 2.2% of total 
cell content) and (D) GLP-1 content in the media plus cells. ** p<0.01 and *** p<0.001 vs. 
basal; ### p<0.001 vs. same treatment in controls.             
                                                                                                                  
Figure 5: Venus-IE-syn1a KO mice demonstrate impaired glucose tolerance during an OGTT. 
(A-C) Body weight (A), small intestinal weight (B) and small intestinal weight normalized to 
body weight (C) in male and female control and IE-syn1a-KO mice. (D-E) mRNA transcript 
levels for Stx1a (D) and Stx isoforms and Gcg (E) in ileal mucosal scrapes from control and IE-
syn1a-KO mice. (F) Control and IE-syn1a KO mice were administered an OGTT at t=0 min 
followed by blood sampling for determination of blood glucose levels (n=9-12 for A-F). (G) 
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RNAseq for syntaxin isoforms in FACS-isolated Venus
+
 vs. Venus
-
 jejunal/ileal epithelial cells 
from female Gcg-Venus mice (inset shows expanded scale; n=3). FPKM, fragments per kilobase 
of exon per million fragments mapped. 
 
Figure 6: 2-Photon microscopy of primary ileal L-cells demonstrates the role of syn1a in 
multiple forms of exocytosis. (A) Representative images and fluorescent intensity tracings of 
single/full SG and multi-granular/compound SG fusion events in Venus-positive L-cells from 
control mice. (B-E) Quantification of the total number of fusion events collected over a 3 min 
basal period and a 12 min forskolin infusion period in control (B) and Venus-IE-syn1a KO (C) 
mice; (D) indicates the same data binned into different phases of secretion (basal: t = -3 to -1 
min; 1
st
 phase: t = 1 to 6 min; and 2
nd
 phase: t = 7 to 12 min) and then classified as full vs. 
compound fusion. The dotted line in (B) indicates best-fit curve for stimulated exocytosis (R
2
 = 
0.82). *p<0.05, ** p<0.01 and *** p<0.001 vs. basal; # p<0.05 and ### p<0.001 vs. the same 
phase in control mice, for total fusion events. (E) Cumulative total fusion events. * p<0.05, ** 
p<0.01 for each time point at t = 4-12 min. n= 9 cells from 6 control mice and 6 cells from 3 IE-
Venus-syn1a KO. 
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SUPPLEMENTAL MATERIALS 
Supplemental Figure Legends 
Figure S1: Body weight (A), intestinal weight (B) and intestinal weight normalized to body 
weight (C) in the male vs. female control and IE-syn1a KO mice shown in Figure 2. 
 
Figure S2: Blood glucose (A), and plasma insulin (B) levels in the male vs. female control and 
IE-syn1a KO mice shown in Figure 3.  
 
Figure S3: Plasma GLP-1 (A), and GIP (B) levels in the male vs. female control and IE-syn1a 
KO mice shown in Figure 3.  
 
Figure S4: (A-B) Male C57Bl/6 mice were administered ileal AdV-RFP (control) or AdV-iCre 
followed by intra-ileal administration of OEA 2 d later, and determination of mucosal Stx1a 
mRNA transcript levels (A) and plasma GLP-1 levels (B; n=3-4). (C-D) AMIC cultures from 
male C57Bl/6 mice were treated with AdV-RFP (control) or AdV-iCre for 2 d, followed by 2 hr 
treatment with vehicle (basal), forskolin plus IBMX or OEA for 2 hr, and determination of cell 
Stx1a mRNA transcript levels (C) and GLP-1 content in the media and cells (D; n=4).   
 
Figure S5: Body weight (A), intestinal weight (B) and intestinal weight normalized to body 
weight (C) in the male vs. female control and Venus-IE-syn1a-KO mice shown in Figure 5. 
 
Figure S6: Blood glucose levels in the male vs. female control and Venus-IE-syn1a KO mice 
shown in Figure 5. 
 
Figure S7: Representative 2-photon images of full and compound fusion events using SRB (red) 
and Venus (green), as visualized in the respective cells shown in Figure 6A. 
 
Supplemental Video 1: Full-field view of a Venus
+
 L-cell (green) surrounded by unlabelled cells. 
Forskolin was added at t = 30 sec. Note the large granule size and multiple fusion events 
occurring in a single neighbouring cell (arrow), consistent with the known properties of mast 
cells. The same video is submitted in both .avi and .mp4 format. 
 
Supplemental Video 2: Single granule, full fusion event at t = 577.8 sec in the membrane of a 
Venus
+
 L-cell. The same video is submitted in both .avi and .mp4 format. 
 
Supplemental Video 3:  Multi-granular, compound fusion event at t = 129.3 – 255.3 sec in the 
membrane of a Venus
+
 L-cell. The same video is submitted in both .avi and .mp4 format. 
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Table S1: Genotyping primers  
Gene Forward Reverse Amplicon 
(bp) 
Annealing 
Temperature 
(
O 
C) 
Stx1a  GCT GCA GAA GCA 
AGA GAA CC 
CAG CCA TAC AAA 
AAC CAC CA 
WT: 404 
Flox: 239 
50.0 
Cre CAA GCC TGG CTC 
GAC GGC C 
CGC GAA CAT CTT 
CAG GTT CT 
390 50.0 
Gcg/GFP AAT TGA GCT CAT 
TTG GAC TGC C 
CTT GCC GTA GGT 
GGC ATC G 
210 50.0 
GFP/GFP CTG GTA GTG GTC 
GGC GAG C 
GTT CAG CGT GTC 
CGG CGA G 
470 
 
50.0 
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Table S2: Antibody table  
Sample  Antigen  Primary Antiserum Secondary Antiserum 
 
Ileal Tissue 
Syntaxin1a Rabbit anti-syn1a, 1:500 
(Abcam cat#41453) 
AlexaFluor488-goat anti-rabbit 
IgG, 1:150 (Life Technologies) 
GLP-1 Mouse anti-GLP-1, 1:400 
(Abcam cat # 23472) 
AlexaFluro555-goat anti-mouse 
IgG, 1:150 (Life Technologies) 
 
AMIC 
Culture 
Syntaxin1a Rabbit anti-syn1a, 1:1000 
(Abcam cat#41453) 
AlexaFluor488-goat anti-rabbit 
IgG, 1:150 (Life Technologies) 
GLP-1 Mouse anti-GLP-1, 1:200 
(Abcam cat # 23472) 
AlexaFluro555-goat anti-mouse 
IgG, 1:150 (Life Technologies) 
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Table S3: qRT-PCR Primer/Probes (all from Applied Biosystems)  
Transcript Product number Exons targeted 
Gcg Mm00801714_m1 5-6 
H3f3a  Mm01612808_g1 3-4 
Stx1a Mm00444008_m1 1-2 
Stx1b Mm01275274_m1 1-2 
Stx2 Mm04229900_m1 2-3 
Stx3 Mm01197689_m1 6-7 
Stx4 Mm00436827_m1 5-6 
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